Apr. 22 at 10:34 AM
$IBRX $MRK $XBI $IBB $TNA
So continuing with numbers discussion and sales potential for just this year in Just USA, lets assume Anktiva captures just 20% of patients(assuming total mkt of 60,000 nmibc patient) or scales to 1,000 new patients per month, i know some will say that’s Pie in the Sky/blue sky shit but I thinks it’s achievable.
So If the company does scale to 1,000 new patients per month, it translates to roughly
$1.44 billion in annual sales.
This is based on the following breakdown of Anktiva's typical treatment cycle and price.
Cost per Patient (Year 1): A standard induction course (6 doses) plus maintenance (typically 9 doses in the first year) totals approximately 15 doses. At an estimated wholesale acquisition cost of
$8,000 per dose, the revenue per patient in their first year is roughly
$120,000.
Total Annual Sales: 12,000 patients ×
$120,000 =
$1.44 Billion.
Thionly covers the first year of treatment. Maintenance therapy can continue for up to three years, so think!
